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To the Editor." 
We thank Drs. Winkler, Karnik, and Slany for their 
interest in our work and are gratified by the increasing 
awareness of the role of fibrinolytic irrigation therapy in 
purulent pericarditis. With regard to their specific queries, 
no echocardiograms were performed uring pericardial 
irrigation. Serial echocardiograms over the period did, 
however, demonstrate a gradual diminution in the size of 
the loculated collections until they disappeared entirely. 
The alterations in left ventricular function as indicated by 
echocardiography and clinical evidence were entirely ben- 
eficial, and no hemodynamic compromise occurred. No 
coagulopathies or arrhythmias developed during the 
course of treatment. 
We agree that urokinase does have a theoretic advan- 
tage over streptokinase in that it is nonantigenic. Uroki- 
nase is far more expensive than streptokinase and is 
currently unavailable in Melbourne public hospitals. In 
addition, we are unaware of a commercially available 
combination of urokinase/streptodornase or streptodor- 
nase alone that could be added to urokinase. Strepto- 
dornase is advantageous in lavage therapy of loculated 
purulent pericarditis because it accelerates the depoly- 
merization of desoxyribose nucleoprotein, thereby lique- 
fying the viscous component of pus. As such, it can work 
synergistically with fibrinolytics, whether streptokinase or
urokinase, to facilitate drainage. It should be noted that 
streptodornase, like streptokinase, is antigenic. 
To date, all documentation regarding the treatment of 
purulent pericarditis with proteolytic and fibrinolytic en- 
zyme lavage has involved small series of patients. Forma- 
tion of antienzymes has not been documented in this 
context. Only a large prospective randomized trial will 
determine the efficacy of adding antibiotics to the lavage 
solution and the relative benefits and risks of adding 
streptodornase to urokinase or using urokinase instead of 
commercially available streptokinase/streptodornase. Our 
good fortune in seeing a decreased incidence of this 
disease over the years also means that such a study would 
have to be multicentered to obtain the numbers required 
to achieve statistically significant results. 
Until now all reported cases have been from groups that 
have developed their own fibrinolytic regimen de novo. 
We hope that the growing awareness of fibrinolytic ther- 
apy in purulent pericarditis will provide treatment options 
for clinicians without he need for further empiric trials in 
isolation from the published literature. 
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